Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 2/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662974 | 0.82 | CES2 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23135856 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14059749 | 0.80 | KDM4E (0.52) | CA12CA1CA2CA9CA14 | |
| SCHEMBL663524 | 0.80 | SERPINE1 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4810126 | 0.79 | ERN1 (0.42) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23413724 | 0.79 | CA12 (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL34472159 | 0.79 | ERN1 (0.36) | CA12CA1CA2CA9CA14 | |
| SCHEMBL10318727 | 0.78 | ERN1 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL21956939 | 0.77 | LMNA (0.39) | CA12CA1CA2CA9CA14 | |
| SCHEMBL10228045 | 0.77 | TUBB1 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4389755-A1 | FLUORESCENT COMPOUND AND FLUORESCENCE-LABELED BIOSUBSTANCE OBTAINED USING SAME | FUJIFILM Corporation (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240110918-A1 | FLUORESCENT COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| CN-117460790-A | Fluorescent compound and fluorescent-labeled biological material using same | 富士胶片株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| WO-2023022187-A1 | FLUORESCENT COMPOUND AND FLUORESCENCE-LABELED BIOSUBSTANCE OBTAINED USING SAME | 富士フイルム株式会社 | 2023-02-23 | — | — | WO | disclosed |
| CN-111377917-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2509960-A1 | TGR5 AGONISTS | Exelixis, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2396304-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | Exelixis, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011071565-A1 | TGR5 AGONISTS | EXELIXIS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010093845-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7119073-B2 | Peptides and their use as inhibitors of hepatitis C virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-10-10 | — | — | US | disclosed |
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | CTRL, VIP, CTSC | CA12 2690/4885CA1 3126/4885CA2 3949/4885 |
| US-20240110918-A1 | FLUORESCENT COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | F11, NPFFR1, FGF23 | CA12 289/4885CA1 485/4885CA2 476/4885 |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CA12 2590/4885CA1 1419/4885CA2 823/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | CA12 2590/4885CA1 1419/4885CA2 823/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CA12 2590/4885CA1 1419/4885CA2 823/4885 |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | CA12 4836/4885CA1 4670/4885CA2 3033/4885 |
| US-20130303505-A1 | TGR5 AGONISTS | GCGR, NPY5R, TBXA2R | CA12 4815/4885CA1 4767/4885CA2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.